Vaccines targeting shared / public neoantigens (e.g. recurrent KRAS and TP53 mutations) — an off-the-shelf alternative to fully personalized manufacture.
STAT’s Adam Feuerstein characterizes 2026 as one of the most consequential years in cancer treatment, citing this mRNA neoantigen success alongside Revolution Medicines’ KRAS drug. The positive late-stage readout signals a major shift in the therapeutic landscape for solid tumors.
Long-term follow-up data from IDH1 vaccination trials provides critical durability signals for shared neoantigen strategies. This evidence supports the viability of targeting common mutations, offering a potential complement to personalized approaches in specific molecular subsets.
Nouscom, a clinical-stage biotech headquartered in Basel, Switzerland, announced receipt of US FDA Fast Track Designation for NOUS-209, a viral vector-based, off-the-shelf neoantigen cancer vaccine, for the prevention of Lynch Syndrome (LS)-associated cancers in carriers with gen…
Researchers developed NeoAPP, a computational tool identifying neoantigens from tumor-specific transcripts (TSTs) rather than just DNA mutations. Applied to 413 PDAC samples, it found a median of 351 neoantigens per sample, significantly exceeding mutation-derived counts. Preclinical data shows these neoTSTs induce CD8+ T cell responses and suppress tumor growth in mouse models, with some detectable in plasma as potential biomarkers.
Providence Health & Services is operating an expanded access program (NCT07614048) for T-cells engineered to express TCRs targeting mutant KRAS-G12D. The intermediate-size IND treats advanced pancreatic and colorectal cancers in patients with specific HLA types. This provides real-world data on the feasibility of manufacturing and administering KRAS-targeted adoptive cell therapy outside of traditional trial structures.
BOSTON, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported preliminary clinical obse…
Primary tumors and their sentinel lymph nodes are functionally linked sites of anti-tumor immunity, yet how T cell receptor (TCR) repertoires are organized across these compartments remains incompletely understood. We thus performed TCR{beta} sequencing on paired primary melanoma…
A study from Vietnam National University developed a colorectal cancer-specific off-the-shelf neoantigen panel targeting shared mutations. By integrating TCGA mutation data with HLA class I binding predictions across 68 alleles, the team identified candidates with broad coverage for both Asian and Caucasian populations to address limitations in population-specific utility.